Cowen and Company’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

Cowen and Company’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-171,536	Closed	-$2.25K	–	597
2024 Q3	$2.25K	Hold	171,536	–	–	﹤0.01%	574
2024 Q2	$7.22K	Sell	171,536 -600	-0.3%	-$38	﹤0.01%	492
2024 Q1	$8.95K	Sell	172,136 -100	-0.1%	-$6	﹤0.01%	519
2023 Q4	$8.61K	Buy	172,236 +72,236	+72%	+$8.18K	﹤0.01%	413
2023 Q3	$22K	Sell	100,000 -3,678	-4%	-$673	﹤0.01%	367
2023 Q2	$13.5K	Sell	103,678 -27,900	-21%	-$2.26K	﹤0.01%	364
2023 Q1	$5.39K	Buy	131,578 +23,678	+22%	+$1.84K	﹤0.01%	459
2022 Q4	$5.39K	Sell	107,900 -50,200	-32%	-$1.88K	﹤0.01%	473
2022 Q3	$9K	Buy	158,100 +33,400	+27%	+$2.01K	﹤0.01%	435
2022 Q2	$11K	Buy	124,700 +25,100	+25%	+$5.57K	﹤0.01%	470
2022 Q1	$36K	Buy	+99,600	New	+$43.9K	﹤0.01%	366

Other funds holding CLDI.WS

EAM

Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return

Cowen and Company's CLDI.WS Position: Q4 2024 in Review

Cowen and Company sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q4 2024, closing a stake of 171,536 shares — an estimated $2.25K sold.

Cowen and Company first reported a position in CLDI.WS in Q1 2022 and held it in 11 quarters. The position peaked at $36K in Q1 2022. 1 fund tracked by Wall St. Rank holds CLDI.WS as of Q4 2024.

Cowen and Company reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q4 2024 after selling out during the quarter.
Cowen and Company sold 171,536 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q4 2024, an estimated $2.25K.
Cowen and Company first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q1 2022 and held it in 11 quarters.
Cowen and Company's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $36K in Q1 2022.
1 fund tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.